Towa PharmaceuticalTOWA PHARMACEUTICAL CO.,LTD.4553東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|---|
| Domestic | +12.8%5y | 126,67614.9% | 155,5387.0% | 178,71512.2% | 206,10313.2% | 216,97612.5% |
| Overseas segment | +9.4%5y | 38,9382.9% | 53,321-0.5% | 49,2180.0% | 53,4900.8% | 56,7340.8% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第70期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第69期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
訂正有価証券報告書－第68期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第67期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第66期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第65期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 52 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.